Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 HKD | +0.88% | -5.79% | -21.92% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
ETFs positioned on Ascletis Pharma Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.23% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.92% | 147M | |
+0.82% | 93.19B | |
0.00% | 39.62B | |
-10.35% | 33.78B | |
+65.34% | 26.82B | |
-16.15% | 15.35B | |
-6.98% | 13.13B | |
-11.77% | 11.6B | |
-49.19% | 10.26B | |
+3.90% | 9.43B |
- Stock Market
- Equities
- 1672 Stock
- Funds and ETFs Ascletis Pharma Inc.